A5041637025- Health Systems, Economic Evaluations, Quality of Life
- Abdominal vascular conditions and treatments
- Liver Diseases and Immunity
- Liver Disease Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Hepatocellular Carcinoma Treatment and Prognosis
- Delphi Technique in Research
- Cancer Immunotherapy and Biomarkers
- Meta-analysis and systematic reviews
- Liver Disease and Transplantation
Cancer Research UK Clinical Trials Unit
2022-2024
University of Birmingham
2022-2024
Primary sclerosing cholangitis is a progressive inflammatory liver disease characterized by biliary and fibrosis. Vascular adhesion protein-1 (VAP-1) important in the process driving We evaluated safety efficacy of VAP-1 blockade with monoclonal antibody (timolumab, BTT1023) patients primary cholangitis.
Background Primary sclerosing cholangitis is a progressive and fibrotic liver disease. Treatments remain inadequate, patients with persistent elevations in activity of alkaline phosphatase are at greatest risk disease progression. Studies patient cohorts have implicated the serum amine oxidase vascular adhesion protein 1 pathophysiology disease, including fibrogenesis. We hypothesised that blockade by monoclonal antibody would result reduction fibrosis/injury, as evaluated tests other...
4012 Background: A previous study by our group using autologous monocyte-derived DC pulsed ex vivo with HepG2 cell lysate showed some clinical benefit evidence of antigen-specific T-cell responses in patients advanced HCC. The current trial reports the activity this vaccine combination TACE All also received low-dose cyclophosphamide to deplete regulatory T cells and thereby enhance vaccination. Methods: Patients intermediate stage HCC (performance status 0-2, Child Pugh A/B7) were...